Preclinical research on Pinealon (EDR tripeptide): epigenetic mechanisms, neuroprotective effects in animal models, and cognitive aging from the Khavinson lab.
NAD+ research in preclinical models reveals sirtuin activation, PARP competition, and mitochondrial effects. Review the evidence on NAD+ and longevity.
Orforglipron GLP-1 research: non-peptide small molecule, oral bioavailability, ATTAIN phase 3 data, and mechanistic comparison to semaglutide and tirzepatide.
Melanotan-2 research covers MC1R and MC4R agonism, skin pigmentation in animal models, and neuroprotective melanocortin signalling in preclinical studies.
Explore 2026 preclinical research on oral peptides metabolic effects — GLP-1, BPC-157, MOTS-c, and NAD+ data from rodent animal model studies reviewed here.
Explore preclinical animal model data on oral GLP-1 appetite regulation, covering food intake, satiety hormones, and hypothalamic GLP-1R activation research.
Preclinical studies on BPC-157 arginate vs acetate salt forms examine degradation rates, pH stability, and oral delivery behaviour in research models.
BPC-157 and GLP-1 longevity research: overlapping mechanisms in metabolic health, cellular repair, mitochondrial function and preclinical anti-aging data.
GLP-1 research compounds vs oral semaglutide: preclinical mechanism comparison, bioavailability data, and what laboratory models show about each compound class.
GLP-1 research compounds explained: native GLP-1, Retatrutide, and Orforglipron. Mechanisms, research applications, and oral capsule delivery. COA verified.
THE STACK · RESEARCH NOTES
125 papers across 8 compound categories.